Traws Pharma, Inc. Common Stock (TRAW)

Price$1.37

Value ScoreB

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-57.18%

Price vs S&P 500 (4W)-37.15%

VGM Score64.57

Market Capitalization$20.53M

P/E Ratio (Annual)2.24x

All Metrics

Book Value / Share (Quarterly)$0.64

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)131.12%

Cash Flow / Share (Quarterly)$-1.51

Price vs S&P 500 (YTD)13.08%

Net Profit Margin (TTM)-616.78%

EPS (TTM)$-2.07

10-Day Avg Trading Volume0.49M

EPS Excl Extra (TTM)$-2.07

EPS (Annual)$1.09

ROI (Annual)-177.55%

Net Profit Margin (5Y Avg)-19456.21%

Cash / Share (Quarterly)$0.31

P/E Basic Excl Extra (TTM)2.49x

P/E Normalized (Annual)2.24x

ROA (Last FY)86.37%

Revenue Growth TTM (YoY)1103.96%

EBITD / Share (TTM)$-2.27

Operating Margin (TTM)-698.31%

Cash Flow / Share (Annual)$-2.01

P/B Ratio4.52x

P/B Ratio (Quarterly)2.90x

Net Income / Employee (Annual)$1,310,000

EV / Revenue (TTM)5.99x

ROA (TTM)-165.91%

EV / EBITDA (TTM)2.12x

EPS Incl Extra (Annual)$1.09

Current Ratio (Annual)0.72x

Quick Ratio (Quarterly)0.38x

3-Month Avg Trading Volume1.58M

52-Week Price Return-7.43%

P/E Incl Extra (TTM)2.49x

Revenue / Employee (TTM)$390,400

Tangible BV / Share (Quarterly)$0.28

P/S Ratio (Annual)7.36x

Asset Turnover (Annual)0.26x

52-Week High$3.27

Operating Margin (5Y Avg)-17720.62%

EPS Excl Extra (Annual)$1.09

26-Week Price Return-49.26%

Quick Ratio (Annual)0.69x

13-Week Price Return-14.38%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.43x

Enterprise Value$17.40M

Asset Turnover (TTM)0.17x

Revenue / Employee (Annual)$398,600

Pretax Margin (Annual)328.67%

Cash / Share (Annual)$0.42

3-Month Return Std Dev120.98%

Net Income / Employee (TTM)$-2,775,300

ROE (Last FY)-177.55%

EPS Basic Excl Extra (Annual)$1.09

Receivables Turnover (TTM)1.64x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.07

Receivables Turnover (Annual)1.00x

ROI (TTM)265.00%

P/S Ratio (TTM)7.07x

Pretax Margin (5Y Avg)-19456.21%

Revenue / Share (Annual)$0.33

Forward P/E2.54x

Price vs S&P 500 (52W)-31.80%

P/E Ratio (TTM)2.49x

Year-to-Date Return21.24%

5-Day Price Return-6.80%

EPS Normalized (Annual)$1.09

ROA (5Y Avg)-148.31%

Net Profit Margin (Annual)328.67%

Month-to-Date Return-6.16%

EBITD / Share (Annual)$-2.13

Operating Margin (Annual)-640.68%

P/E Excl Extra (TTM)2.49x

EPS Basic Excl Extra (TTM)$-2.07

P/TBV (Quarterly)6.68x

Pretax Margin (TTM)-616.78%

Price vs S&P 500 (13W)-22.63%

Beta1.47x

Revenue / Share (TTM)$0.26

ROE (TTM)265.00%

52-Week Low$0.99

vGradeB

gGradeA

mGradeD

vgmGradeB

Show chart for

Earnings Surprise History

Q4 250.63est. -1.25

Q1 26-0.53est. -0.75

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

4.25

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TRAWTraws Pharma, Inc. Common Stock	B	A	D	$1.37
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Traws Pharma is a clinical-stage biopharmaceutical company developing antiviral therapies for respiratory viral diseases, with a focus on resistant strains. The company is advancing three product candidates: Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.